- Home
- LDTC vs RNAZ Comparison
LDTC vs RNAZ Comparison
Compare LDTC & RNAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LDTC
- RNAZ
- Stock Information
- Founded
- LDTC 2007
- RNAZ 2016
- Country
- LDTC Canada
- RNAZ United States
- Employees
- LDTC N/A
- RNAZ N/A
- Industry
- LDTC Blank Checks
- RNAZ Biotechnology: Pharmaceutical Preparations
- Sector
- LDTC Finance
- RNAZ Health Care
- Exchange
- LDTC Nasdaq
- RNAZ Nasdaq
- Market Cap
- LDTC 7.9M
- RNAZ 8.3M
- IPO Year
- LDTC N/A
- RNAZ 2021
- Fundamental
- Price
- LDTC $0.32
- RNAZ $0.34
- Analyst Decision
- LDTC Buy
- RNAZ Strong Buy
- Analyst Count
- LDTC 3
- RNAZ 1
- Target Price
- LDTC $1.00
- RNAZ $3.00
- AVG Volume (30 Days)
- LDTC 157.6K
- RNAZ 599.4K
- Earning Date
- LDTC 08-14-2024
- RNAZ 11-26-2024
- Dividend Yield
- LDTC N/A
- RNAZ N/A
- EPS Growth
- LDTC N/A
- RNAZ N/A
- EPS
- LDTC N/A
- RNAZ N/A
- Revenue
- LDTC $6,052,694.00
- RNAZ N/A
- Revenue This Year
- LDTC N/A
- RNAZ N/A
- Revenue Next Year
- LDTC $2.28
- RNAZ $100.00
- P/E Ratio
- LDTC N/A
- RNAZ N/A
- Revenue Growth
- LDTC 2.76
- RNAZ N/A
- 52 Week Low
- LDTC $0.22
- RNAZ $0.22
- 52 Week High
- LDTC $11.20
- RNAZ $18.68
- Technical
- Relative Strength Index (RSI)
- LDTC 59.16
- RNAZ 32.40
- Support Level
- LDTC $0.28
- RNAZ $0.31
- Resistance Level
- LDTC $0.35
- RNAZ $0.49
- Average True Range (ATR)
- LDTC 0.04
- RNAZ 0.05
- MACD
- LDTC 0.01
- RNAZ -0.02
- Stochastic Oscillator
- LDTC 75.97
- RNAZ 9.64
About LDTC LeddarTech Holdings Inc.
LeddarTech Holdings Inc is a company that develops and provides comprehensive perception software solutions that enable the deployment of ADAS and autonomous driving (AD) applications. Its automotive-grade software applies AI and computer vision algorithms to generate accurate 3D models of the environment, allowing for decision-making and safer navigation.
About RNAZ TransCode Therapeutics Inc.
TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.